ProQR Therapeutics (PRQR) Common Equity (2012 - 2026)

ProQR Therapeutics has reported Common Equity for 15 years, with the latest figure at $44.0 million in Q1 2026.

• Quarterly Common Equity fell 46.99% year-over-year to $44.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.0 million (down 46.99% YoY) and the FY2025 annual result came in at $57.5 million, down 39.27% from the prior year.
• Common Equity eased to $44.0 million in Q1 2026 per PRQR's latest filing, from $57.5 million in the prior quarter.
• Over five years, Common Equity peaked at $113.8 million in Q1 2022 and troughed at $27.4 million in Q3 2024.
• A 5-year average of $63.7 million and a median of $63.0 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity plunged 54.57% in 2022, then jumped 143.18% in 2025.
• Over 5 years, Common Equity stood at $68.0 million in 2022, then tumbled by 34.54% to $44.5 million in 2023, then surged by 112.5% to $94.6 million in 2024, then tumbled by 39.27% to $57.5 million in 2025, then declined by 23.41% to $44.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $44.0 million, $57.5 million, and $66.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.